Table 3.
Comparison of overall tumour BED gains for conventional and delayed acceleration regimen for each BED-equivalent repopulation rate (K)
| K (Gy/day) | Phase-2 Dose per fraction (Gy) | Phase-2 Total dose (Gy) | Total BED10Gy novel regimen | Total BED10Gy conventional regimen | Absolute BED gain in 2 Gy equivalent dose | Total BED3Gy novel regimen | Total BED3Gy conventional regimen | Absolute BED gain in 2 Gy equivalent dose |
|---|---|---|---|---|---|---|---|---|
| 0.6 | 2.65 | 26.5 | 77.3 | 73.2 | 3.4 | 112.4 | 105.9 | 3.9 |
| 0.7 | 3.08 | 24.64 | 76.7 | 71.4 | 4.4 | 113.1 | 104.1 | 5.4 |
| 0.8 | 3.37 | 23.59 | 76.3 | 69.6 | 5.6 | 113.6 | 102.3 | 6.8 |
| 0.9 | 3.72 | 22.32 | 75.9 | 67.8 | 6.8 | 114 | 100.5 | 8.1 |
BED, biological effective dose.
The phase-1 fractionation is 40Gy in 20 fractions and the corresponding phase-1 and phase-2 BEDs are added to obtain the total BED.